comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NOs:2-10; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NOs:16-22. In some examples, the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:11-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:23-24. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-24. In any of the examples herein, the composition may further comprise a pharmaceutically acceptable carrier. In any of the examples herein, the binding affinity and/or binding avidity of the antibody to a human Siglec-8 can be higher than the binding affinity and/or binding avidity of antibody 2E2 or 2C4 to the human Siglec-8. In any of the examples herein, the antibody may have a Tm of at least about 70ºC to at least about 72ºC in a thermal shift assay. In some examples, the antibody has a Tm of about 70ºC, about 71ºC, or about 72ºC. In some examples, the antibody has the same or higher Tm as compared to a chimeric 2C4 antibody. In some examples, the antibody has the same or higher Tm as compared to an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO:84 and a light chain comprising the amino acid sequence of SEQ ID NO:85.

[0024a] In one aspect, the present disclosure refers to a kit comprising the composition as disclosed herein.

[0024b] In one aspect, the present disclosure refers to the composition as disclosed herein for use in therapy.

[0024c] In one aspect, the present disclosure refers to use of the composition as disclosed herein in the manufacture of a medicament for treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, wherein the disease is selected from the group consisting of: asthma, allergic rhinitis, nasal polyposis, atopic dermatitis, chronic urticaria, mastocytosis, eosinophilic leukemia, hypereosinophilic syndrome, pauci granulocytic asthma, acute or chronic airway hypersensitivity, eosinophilic esophagitis, Churg-Strauss syndrome, inflammation associated with a cytokine, inflammation associated with cells expressing Siglec-8, malignancy associated with cells expressing Siglec-8, physical urticaria, cold urticaria, pressure-urticaria, bullous pemphigoid, food allergy, and allergic bronchopulmonary aspergillosis (ABPA).

[0025] In another example, provided herein is a method of treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, the method comprising administering to the subject an effective amount of an antibody described herein or an antigen-binding fragment thereof or a composition described herein. In some examples, the disease is an eosinophil mediated-disease. In some examples, the disease is a mast cell mediated-disease. In some

CLAIMS

WHAT IS CLAIMED IS:

1. A composition comprising an antibody that specifically binds to human Siglec-8, wherein the antibody comprises a human IgG1 Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains contain a fucose residue.

2. The composition of claim 1, wherein ~~substantially none~~less than 0.5% of the N-glycoside-linked carbohydrate chains contain a fucose residue.

3. The composition of claim 1 or claim 2, wherein the antibody is a humanized or human antibody.

4. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66.

5. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-10, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16-22.

6. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71.

7. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:11-14, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:23-24.

8. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-14, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16-24.

9. The composition of any one of claims 1-8, further comprising a pharmaceutically acceptable carrier.

~~10. The composition of any one of claims 1-9, wherein the binding affinity or avidity of the antibody to a human Siglec-8 is higher than the binding affinity or avidity of antibody 2E2 or 2C4 to the human Siglec-8.~~

~~11.~~10. The composition of any one of claims 1-~~10~~9, wherein the antibody has a Tm of at least about 70ºC in a thermal shift assay.

~~12.~~11. The composition of claim ~~11~~10, wherein the antibody has a Tm of at least about 70ºC to at least about 72ºC in a thermal shift assay.

~~13.~~12. A kit comprising the composition of any one of claims 1-~~12~~11.

~~14.~~13. The composition of any one of claims 1-~~12~~11 for use in therapy.

~~15.~~14. Use of the composition of any one of claims 1-~~12~~11 in the manufacture of a medicament for treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, wherein the disease is selected from the group consisting of: asthma, allergic rhinitis, nasal polyposis, atopic dermatitis, chronic urticaria, mastocytosis, eosinophilic leukemia, hypereosinophilic syndrome, pauci granulocytic asthma, acute or chronic airway hypersensitivity, eosinophilic esophagitis, Churg-Strauss syndrome, inflammation associated with a cytokine, inflammation associated with cells expressing Siglec-8, malignancy associated with cells expressing Siglec-8, physical urticaria, cold urticaria,

pressure-urticaria, bullous pemphigoid, food allergy, and allergic bronchopulmonary aspergillosis (ABPA).

~~16. The use according to claim 15, wherein the disease is an eosinophil mediated-disease.~~

~~17. The use according to claim 15, wherein the disease is a mast cell mediated-disease.~~

~~18.~~15. The use according to claim ~~15~~14, wherein the composition inhibits one or more symptoms of an allergic reaction.

~~19.~~16. The use according to claim ~~18~~15, wherein the allergic reaction is a Type I hypersensitivity reaction.

~~20. The use according to claim 15, wherein the disease is selected from the group consisting of: asthma, allergic rhinitis, nasal polyposis, atopic dermatitis, chronic urticaria, mastocytosis, eosinophilic leukemia, and hypereosinophilic syndrome.~~

~~21. The use according to claim 15, wherein the disease is selected from the group consisting of: pauci granulocytic asthma, acute or chronic airway hypersensitivity, eosinophilic esophagitis, Churg-Strauss syndrome, inflammation associated with a cytokine, inflammation associated with cells expressing Siglec-8, malignancy associated with cells expressing Siglec-8, physical urticaria, cold urticaria, pressure-urticaria, bullous pemphigoid, food allergy, and allergic bronchopulmonary aspergillosis (ABPA).~~

~~22.~~17. The use according to any one of claims ~~15-21~~14-16, wherein the subject is suffering from asthma that is not adequately controlled by an inhaled corticosteroid, a short acting β2 agonist, a long acting β2 agonist, or a combination thereof.

~~23.~~18. The use according to any one of claims ~~15-22~~14-17, wherein the subject is a human.